cyc 682 has been researched along with daunorubicin in 1 studies
| Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (daunorubicin) | Trials (daunorubicin) | Recent Studies (post-2010) (daunorubicin) |
|---|---|---|---|---|---|
| 30 | 5 | 18 | 8,239 | 886 | 1,310 |
| Protein | Taxonomy | cyc 682 (IC50) | daunorubicin (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 1.9 | |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | 8 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.047 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.22 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
1 review(s) available for cyc 682 and daunorubicin
| Article | Year |
|---|---|
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |